中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2015年
3期
97-98
,共2页
许英铭%梁心慧%谢月恒%陆永钊
許英銘%樑心慧%謝月恆%陸永釗
허영명%량심혜%사월항%륙영쇠
胃炎%四联疗法%幽门螺杆菌
胃炎%四聯療法%幽門螺桿菌
위염%사련요법%유문라간균
Gastritis%Quadruple therapy%Helicobacter pylori
目的:探究利用三联疗法和荆花胃康胶丸组成的新四联疗法治疗幽门螺杆菌相关性胃炎的疗效。方法:随机将472例相关性胃炎患者分成对照组和观察组,对照组244例患者使用三联疗法联合胶体果胶铋治疗;观察组228例患者使用三联疗法联合荆花胃康胶丸治疗。跟踪观察两组患者的临床症状改善情况和药物不良反应。结果:对照组出现13例不良反应,观察组出现1例不良反应(P<0.01),幽门螺杆菌根除率分别为89.18%(206/231)和85.46%(194/227)。在治疗1周后、8周后,对比两组幽门螺杆菌相关性胃炎患者的临床症状,可见观察组的临床症状得到显著的改善(Uc=2.387/2.413,P<0.05)。结论:新四联疗法在临床症状方面的改善和药物安全性方面比含铋四联疗法的效果显著。
目的:探究利用三聯療法和荊花胃康膠汍組成的新四聯療法治療幽門螺桿菌相關性胃炎的療效。方法:隨機將472例相關性胃炎患者分成對照組和觀察組,對照組244例患者使用三聯療法聯閤膠體果膠鉍治療;觀察組228例患者使用三聯療法聯閤荊花胃康膠汍治療。跟蹤觀察兩組患者的臨床癥狀改善情況和藥物不良反應。結果:對照組齣現13例不良反應,觀察組齣現1例不良反應(P<0.01),幽門螺桿菌根除率分彆為89.18%(206/231)和85.46%(194/227)。在治療1週後、8週後,對比兩組幽門螺桿菌相關性胃炎患者的臨床癥狀,可見觀察組的臨床癥狀得到顯著的改善(Uc=2.387/2.413,P<0.05)。結論:新四聯療法在臨床癥狀方麵的改善和藥物安全性方麵比含鉍四聯療法的效果顯著。
목적:탐구이용삼련요법화형화위강효환조성적신사련요법치료유문라간균상관성위염적료효。방법:수궤장472례상관성위염환자분성대조조화관찰조,대조조244례환자사용삼련요법연합효체과효필치료;관찰조228례환자사용삼련요법연합형화위강효환치료。근종관찰량조환자적림상증상개선정황화약물불량반응。결과:대조조출현13례불량반응,관찰조출현1례불량반응(P<0.01),유문라간균근제솔분별위89.18%(206/231)화85.46%(194/227)。재치료1주후、8주후,대비량조유문라간균상관성위염환자적림상증상,가견관찰조적림상증상득도현저적개선(Uc=2.387/2.413,P<0.05)。결론:신사련요법재림상증상방면적개선화약물안전성방면비함필사련요법적효과현저。
Objective:To explore the curative effect of using new quadruple therapy composed of triple therapy and Jing Hua Wei Kang capsule in the treatment of helicobacter pylori associated gastritis.Methods:472 patients with associated gastritis were randomly divided into the control group and the observation group.244 patients in the control group were treated by triple therapy combined with colloidal bismuth pectin.228 patients in the observation group were treated by triple therapy combined with Jing Hua Wei Kang capsule.The clinical symptoms improvement and adverse drug reactions of patients in two groups were tracking observed.Results:The control group appeared 13 cases of adverse reactions,and the observation group appeared 1 case of adverse reaction(P<0.01).The Helicobacter pylori eradication rates were respectively 89.18% (206/231) and 85.46% (194/227).After 1 week and 8 weeks treatment,the clinical symptoms of patients with helicobacter pylori associated gastritis in two groups were compared,the clinical symptom of the observation group were improved significantly(Uc=2.387/2.413,P<0.05).Conclusion:In the clinical symptoms improvement and medication safety,the effect of new quadruple therapy is significant than containing bismuth quadruple therapy.